{"generic":"Tafamidis Meglumine","drugs":["Tafamidis Meglumine"],"mono":{"0":{"id":"jxvhs0","title":"Generic Names","mono":"Tafamidis Meglumine"},"1":{"id":"jxvhs1","title":"Dosing and Indications","sub":[{"id":"jxvhs1b4","title":"Adult Dosing","mono":"<ul><li>tafamidis has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li>if vomiting occurs after administration and capsule is not identified, no additional dose is necessary; if capsule is identified, administer another dose<\/li><li><b>Amyloidogenic transthyretin amyloidosis - Polyneuropathy, Stage 1; symptomatic:<\/b> 20 mg ORALLY once daily added to standard of care (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jxvhs1b5","title":"Pediatric Dosing","mono":"no relevant use in pediatric patients younger than 18 years "},{"id":"jxvhs1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dose adjustment necessary<\/li><li><b>hepatic impairment (mild to moderate):<\/b> no dose adjustment necessary<\/li><li><b>elderly (65 years or older):<\/b> no dose adjustment necessary<\/li><\/ul>"},{"id":"jxvhs1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Amyloidogenic transthyretin amyloidosis - Polyneuropathy, Stage 1; symptomatic<br\/>"}]},"3":{"id":"jxvhs3","title":"Contraindications\/Warnings","sub":[{"id":"jxvhs3b9","title":"Contraindications","mono":"hypersensitivity to tafamidis or any component of the product <br\/>"},{"id":"jxvhs3b10","title":"Precautions","mono":"<ul><li>hepatic impairment, severe<\/li><li>hereditary fructose intolerance; product contains sorbitol<\/li><li>pregnancy should be avoided; effective contraception required during therapy and for 1 month after therapy discontinuation<\/li><\/ul>"},{"id":"jxvhs3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxvhs3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"jxvhs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (10% or greater), Upper abdominal pain (1% to less than 10%)<\/li><li><b>Renal:<\/b>Urinary tract infectious disease (10% or greater)<\/li><li><b>Reproductive:<\/b>Infective vaginitis (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"jxvhs6","title":"Drug Name Info","sub":{"2":{"id":"jxvhs6b19","title":"Class","mono":"Neuropathic Pain Agent<br\/>"},"3":{"id":"jxvhs6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxvhs9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>swallow capsules whole, do not crush or cut<\/li><li>take with or without food<\/li><\/ul>"}}}